Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06187077 · ClinicalTrials.gov registry record · NA

Techquity by FAITH!

A NA study of Cardiovascular Diseases and Health Equity, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT06187077: Recruiting NA study of Cardiovascular Diseases and Health Equity, sponsored by Mayo Clinic.

NCT06187077 is a NA study of Cardiovascular Diseases and Health Equity that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06187077, a NA study of Cardiovascular Diseases and Health Equity, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to engage African-American churches via an established community-academic partnership (FAITH! Program) to build capacity to promote cardiovascular health and digital health equity in African-American faith communities. There are 3 study aims: Aim 1: Co-design a culturally tailored digital health equity toolkit with community members Aim 2: Train a network of Digital Health Advocates (DHAs) in digital health equity and cardiovascular health promotion Aim 3: Test the impact of a DHA-enhanced mobile health intervention (the FAITH! App) on cardiovascular health and digital health readiness among participants In Aim 1, participants will attend a series of focus groups to share their input on a digital health equity curriculum that will be condensed into a toolkit. In Aim 2, DHAs will be trained using this toolkit as well as a community health advocacy curriculum to learn how to promote digital health readiness and cardiovascular health in their communities. Finally, Aim 3 will be a randomized controlled trial where participants will use the FAITH! App to improve their cardiovascular health. Some participants will have the added support of a DHA, and the control group participants will use the app with no additional support to test whether the DHA support is associated with a more significant improvement in cardiovascular health.

Primary Outcome

Changes from baseline in Life's Essential 8 score. Life's Essential 8 composite score is determined as a composite of all components by calculating an unweighted average score on a scale of 0 to 100 points. An overall cardiovascular health score (Life's Essential 8 score) will be considered high (80 to 100 points), moderate (50 to 79 points) or low for (0 to 49 points).

Interventions

  • BEHAVIORAL DHA-Enhanced FAITH! App
  • BEHAVIORAL FAITH! App

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-07-11
Est. Completion 2026-06-30
Phase NA
Mayo Clinic

2,844 total trials

What NCT06187077 shows while recruiting

NCT06187077 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which DHA-Enhanced FAITH! App is the first listed.

NCT06187077 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06187077 about?

NCT06187077 is a clinical study titled "Techquity by FAITH!". The goal of this clinical trial is to engage African-American churches via an established community-academic partnership (FAITH! Program) to build capacity to promote cardiovascular health and digital health equity in African-American faith communities. There are 3 study aims: Aim 1: Co-design a cu...

What is the current status of trial NCT06187077?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-07-11. Estimated completion is 2026-06-30.

What conditions does trial NCT06187077 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Health Equity.

What interventions are being tested in trial NCT06187077?

The interventions under investigation include: DHA-Enhanced FAITH! App (BEHAVIORAL), FAITH! App (BEHAVIORAL).

Who is sponsoring clinical trial NCT06187077?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06187077 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06187077's enrollment target sits among peer trials

200 145th of 300 higher than 146 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06187077, the US trial registry maintained by the National Library of Medicine. NCT06187077 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.